Superluminal Medicines raises $60.0M Series B (United States, Sep 2026)
Reach the investors backing rounds like this
Backed by BVF Partners, L.P., Deep Track Capital +6 more · verified emails and LinkedIn on Datapile
Superluminal Medicines Raises $60M Series B to Advance Obesity Drug - Unite.AI
Superluminal Medicines is a biotechnology company using AI and machine learning for drug discovery. They focus on rare genetic forms of obesity and hypothalamic obesity. This Series B funding will advance their lead program for rare genetic forms of obesity toward a first clinical trial.
Superluminal Medicines Raises $60M Series B to Advance Obesity Drug Unite.AI
| Oct 08, 2026 | Natron Energy | $10.2M | — | United States |
| Oct 08, 2026 | Hone | $60.0M | Seed | United States |
| Oct 08, 2026 | Arena | $200.0M | Series B | United States |
| Oct 08, 2026 | Quaise Energy | $25.0M | Grant | United States |
21,967 investors back startups in United States
You just read who funded Superluminal Medicines. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.